Inhibikase Therapeutics, Inc. Common Stock (IKT)
Inhibikase Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing kinase inhibitors for the treatment of neurodegenerative and infectious diseases. The company's approach involves targeting aberrant kinase activity involved in disease progression, aiming to create therapies with improved safety and efficacy profiles. Founded with an emphasis on precision medicine, Inhibikase leverages its expertise in kinase biology to advance novel therapeutic candidates.
Company News
A Polish credit bureau analysis reveals that including Buy Now Pay Later (BNPL) transaction data in credit histories could help nearly 40% of 'thin-file' bank customers improve their creditworthiness, with BNPL transactions showing high repayment rates and low default risks.
The article discusses 10 small-cap stocks that could outperform in 2025, citing factors like falling interest rates, low valuations, and potential shifts in industrial production.
HC Wainwright & Co. has decided to maintain its Buy rating of Inhibikase Therapeutics (NASDAQ:IKT) and raise its price target from $27.00 to $27.00. Shares of Inhibikase Therapeutics are trading down 4.44% over the last 24 hours, at $2.15 per share. A move to $27.00 would account for a 1155.81% increase from the current share price. About Inhibik...
Inhibikase Therapeutics, Inc. (IKT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Penny stocks to watch after big news this week The post Penny Stocks To Buy? 4 To Watch Now After Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.